Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Vence

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cancer Immunology Research|July 29, 2015
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case ReportIsabella C Glitza, Cara Haymaker, Chantale Bernatchez, et al.
Nature Medicine|December 25, 2019
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastomaSangeeta Goswami, Thomas Walle, Andrew E Cornish, et al.
Science Translational Medicine|April 3, 2020
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancerSumit K Subudhi, Luis Vence, Hao Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Characterization and Comparison of GITR Expression in Solid TumorsLuis Vence, Samantha L Bucktrout, Irina Fernandez Curbelo, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2019
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancerJorge Blando, Anu Sharma, Maria Gisela Higa, et al.
The Lancet. Oncology|February 23, 2017
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 studyVan K Morris, Mohamed E Salem, Halla Nimeiri, et al.
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.
Nature Medicine|July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cancer Immunology Research|July 29, 2015
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case ReportIsabella C Glitza, Cara Haymaker, Chantale Bernatchez, et al.
Nature Medicine|December 25, 2019
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastomaSangeeta Goswami, Thomas Walle, Andrew E Cornish, et al.
Science Translational Medicine|April 3, 2020
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancerSumit K Subudhi, Luis Vence, Hao Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Characterization and Comparison of GITR Expression in Solid TumorsLuis Vence, Samantha L Bucktrout, Irina Fernandez Curbelo, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2019
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancerJorge Blando, Anu Sharma, Maria Gisela Higa, et al.
The Lancet. Oncology|February 23, 2017
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 studyVan K Morris, Mohamed E Salem, Halla Nimeiri, et al.
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.
Nature Medicine|July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.
Pageof 3